渣打銀行助河南投資集團首次發行境外美元債券
渣打銀行公布,為河南投資集團擔任聯席全球協調人及評級顧問,助其首次發行境外美元債券。該筆債券期限為三年,在最終價格指引公告前訂單規模超過57億美元,超額認購19倍,受到大量來自香港、新加坡及歐洲的專業投資機構青睞,其中包括知名保險、大型資產管理、基金等多類型全球固定收益投資者。初始指導價為2.9厘區間,最終指導價及票息為2.2厘,發行規模3億美元,創今年以來中國中部地區省級企業同年期境外美元債發行收益率最低紀錄。
渣打資本市場大中華及北亞地區主管嚴守敬,河南投資集團此次成功發行首筆境外債,得到境外投資者的踴躍支持,表明國際投資者對河南省內優質平台資產已經全面恢復信心,有助提升河南省在國際資本市場的形象。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.